© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a máximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.
Alameda, F., Velarde, J. M., Carrato, C., Vidal, N., Arumí, M., Naranjo, D., Martinez-Garcia, M., Ribalta, T., & Balañá, C. (2019). Prognostic value of stem cell markers in glioblastoma. Biomarkers, 24, 677-683. https://doi.org/10.1080/1354750X.2019.1652345